XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Business Combination (Tables)
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Schedule of Summarizes the Purchase Price in the Merger

The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):

Schedule of Estimated Share Consideration of Combined Company
(1)
Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:

 

Number of shares of the combined company owned by
 resTORbio stockholders (a)

 

 

5,207,695

 

Multiplied by the fair value per share of resTORbio common stock (b)

 

$

16.59

 

Acquisition date fair value of resTORbio

 

 

86,396

 

Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)

 

 

626

 

Less: portion of the fair value to be distributed as CVR (c)

 

 

(2,880

)

Fair value of shares of the combined company owned by resTORbio stockholders

 

$

84,142

 

Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired

The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):

 

 

 

As of
December 31,
2020

 

 

Measurement
Period
Adjustments

 

 

Final Purchase
Price Allocation

 

Net assets acquired:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

63,869

 

 

$

 

 

$

63,869

 

Prepaid expenses and other current assets

 

 

3,059

 

 

 

615

 

 

 

3,674

 

Property and equipment

 

 

318

 

 

 

 

 

 

318

 

IPR&D

 

 

3,490

 

 

 

 

 

 

3,490

 

Restricted cash

 

 

245

 

 

 

 

 

 

245

 

Accounts payable

 

 

(1,316

)

 

 

 

 

 

(1,316

)

Accrued and other current liabilities

 

 

(2,365

)

 

 

12

 

 

 

(2,353

)

Other liabilities

 

 

 

 

 

 

 

 

 

Deferred tax liability

 

 

(367

)

 

 

 

 

 

(367

)

Goodwill

 

 

20,089

 

 

 

(627

)

 

 

19,462

 

Purchase price

 

$

87,022

 

 

$

 

 

$

87,022

 

Schedule of changes in the Company’s IPR&D and CVR since the Merger

The following tables present changes in the Company’s IPR&D and CVR since the Merger (in thousands):

 

 

 

Acquisition Date
Fair value as of
September 15, 2020

 

 

Change in
Fair value

 

 

As of
December 31,
2020

 

 

Change in
Fair value

 

 

As of
September 30,
2021

 

In-process research and development

 

$

3,490

 

 

$

(2,300

)

 

$

1,190

 

 

$

(1,190

)

 

$

 

Contingent Value Rights

 

$

2,880

 

 

$

(1,900

)

 

$

980

 

 

$

(980

)

 

$